Sign up for news & promotions:
iCas9-T2A-antiCD19scFv-CD28-CD3z
| Item Information | ||
|---|---|---|
| Catalog # | Size/Concentration | Price |
| PM-CAR1006 | 1x10^6 cells | $1200.00 |
| 2x10^6 cells | $1800.00 | |
| 1x10^7 cells | $4800.00 | |
| 1x10^9 cells | $0.00 | |
| Specification | |
|---|---|
| Product Order | I |
| Shipping Information | This product will ship in a box containing dry ice at a temperature of -80°C. Learn More |
Images
Illustration of CAR construct
Figure 1: CAR-T cells expressing the above construct are available from Promab targeting CD19 with inducible
Positive control measured with flow cytometry
Figure 2: Flow cytometry with Fab Ab showing expression of scFv icasp9-CD19 CAR T-cells.
Negative control measured with flow cytometry
Figure 3: T cells that have not been transfected.
Product Overview
| Description | The inducible caspase-9-CD19 CAR construct consists of FKBP12 gene with mutation F36 to V coding two 12 kDa FK506 binding proteins fused to truncated Caspase9 (135-416; lacking pro-domain), followed by T2A peptide and then CD19scFv-CD28-CD3zeta. Administration of chemical inductor of dimerization (CID) CID (AP1903 or AP20187) results in dimerization of caspase 9 leading to an activated form of the molecule, which then initiates an apoptotic signaling leading to apoptosis of the transduced cell. Introduction of inducible caspase-9 is used for increasing safety of CAR-T cells by decreasing cytotoxicity of CAR-T cells in the presence of dimerization agent. |
|---|